Entering text into the input field will update the search result below

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Clovis Oncology, Inc. (CLVS) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET

Company Participants

Anna Sussman - IR

Patrick Mahaffy - CEO

Thomas Harding - Chief Scientific Officer

Lindsey Rolfe - Chief Medical Officer

Dan Muehl - CFO

Conference Call Participants

Gavin Scott - JPMorgan

Tazeen Ahmad - Bank of America

Paul Choi - Goldman Sachs

Andrew Berens - SVB Leerink

Joe Catanzaro - Piper Sandler


Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology Q2 2021 Operating Results Webcast Conference call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker, Anna Sussman, Vice President of Investor Relations. Thank you. Please go ahead.

Anna Sussman

Thank you, Bella. Good morning, everyone. Welcome to the Clovis Oncology Second Quarter 2021 Conference Call. Thanks for joining us. You've likely seen this morning's press release, and if not, it's available on our website at clovisoncology.com. As a reminder, this conference call is being recorded and webcast. Remarks may be accessed live on our website during the call and will be available on our archive for the next several weeks.

Today's agenda includes the following, Patrick Mahaffy, our President and CEO, will discuss the highlights of today's corporate update; and then Dr. Thomas Harding, our Chief Scientific Officer, will present an update on our FAP-2286 and targeted radionuclide therapy development programs; Dr. Lindsey Rolfe, our Chief Medical Officer, will discuss the anticipated upcoming clinical milestones for Rubraca and F2286; then Dan Muehl, our Chief Financial Officer, will cover this quarter's results in greater detail. Patrick will make a few brief remarks -- sorry, a few brief -- a brief review of corporate strategy and make a few closing remarks. And then we'll open the call for Q&A, during which John, Pat and Tom and Linde will be available for questions.

Recommended For You

Comments (1)

Clown Pat so proud of... "And lastly, I'm pleased to announce that during the quarter, we raised $72.5 million in net proceeds through our at the market or ATM equity offering program" It's called DILUTION and nothing to be pleased about. What a clown - raping the equity holders in order to pay his and the c suites OUTLANDISH compensation packages. Folks, HOW MANY dilutions have occurred in the last couple of years to keep this fraud going on? And its GUARANTEED another one is cooking before years end (in order to pay for next years absurd compensation package).
As expected, Pat using covid as an excuse for poor sales. Please dog, give it up that's last years excuse. Look at GBT - they used that excuse last year and got whacked but lo and behold their sales last q were smashing. No covid excuse for them.
Why the pps is holding up is beyond me, but I suspect this pos is going to $1 within a year (especially when Pat's covid excuses has run out). Strong sell
One last thing, as you can tell by the comments - NOBODY gives a rats azz about CLVS. Rightfully so.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.